2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

查看全文 作　　者：Yong [1]Huo;Young-Hoon [2]Jeong;Yanjun [1]Gong;Daowen [3]Wang;Ben [4]He;Jiyan [5]Chen;Guosheng [6]Fu;Yundai [7]Chen;Jianping [1]Li;Yi [8]Li;Shinya [9]Goto;Udaya [10]S.Tantry;Paul [10]A.Gurbel;Jong-Hwa [2]Ahn;Hyo-Soo [11]Kim;Myung Ho [12]Jeong;Yaling [8]Han;Sidney C.Smith [13]Jr.;Junbo [14]Ge

机构地区：[1]Department of Cardiology, Peking University First Hospital;[2]Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University, Changwon Hospital;[3]Division of Cardiology, Internal Medicine Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology;[4]Department of Cardiology, Shanghai Chest Hospital affiliated to Shanghai Jiaotong University;[5]Department of Cardiology, Guangdong General Hospital;[6]Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine;[7]Department of Cardiology, Chinese PLAG General Hospital;[8]Department of Cardiology, General Hospital of Northern Theater Command;[9]Department of Medicine (Cardiology), Tokai University School of Medicine;[10]Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute;[11]Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital;[12]The Heart Research Center Nominated by Korea Ministry of Health and Welfare, Chonnam National University Hospital;[13]Division of Cardiology, University of North Carolina;[14]Department of Cardiology, Fudan University Zhongshan Hospital

出　　处：《Science Bulletin》索引2019年第64卷第3期,共14页

基　　金：partly supported by the National Research Foundation (NRF) Republic of Korea (NRF-2015R1A5A2008833) 摘　　要：East Asians are the most populous race in the world and their health status is an important global issue.Compared with Caucasian populations, East Asian patients have a different benefit/risk ratio when using antithrombotic treatment. Despite this observation, treatment strategies in East Asian patients are mostly based on the American and European guidelines. Despite a lower platelet inhibitory response to clopidogrel, East Asian patients show a similar or even a lower rate of ischemic event occurrence and higher bleeding risk compared with Caucasian patients. For potent P2Y_(12) inhibitors(ticagrelor and prasugrel),East Asian patients have shown less favorable net clinical benefits compared with Caucasian patients,which may be related to differences in pharmacokinetic/pharmacodynamic profiles and therapeutic zone of antiplatelet effect. This updated consensus mainly focuses on state-of-the-art and current controversies in the East Asian population. In addition, when East Asian patients are administered potent P2Y_(12) receptor inhibitors, the strategies and ongoing trials to overcome the related hurdles are discussed. 关键词：East Asian CORONARY ARTERY disease ANTIPLATELET BLEEDING

相关文献

参考文献（119）
引证文献（13）
耦合文献（34）

参考文献(119)

引证文献(13)

耦合文献(34)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI

参考文献(119)

引证文献(13)

耦合文献(34)

用户提示